A study investigating the invasive potential of CD133+ endometrial cancer cells found that CD133+ cells had CSC potential and showed resistance towards chemotherapeutic drugs such as cisplatin and paclitaxel. The gene discussed is PROM1; the disease is endometrial cancer.